Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
326030.KS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-298.00
vs -579.77
Q3.23
N/A
-235.00
vs -191.00
Q4.23
+115%
86.32
vs -560.00
Q1.24
+647%
164
vs -30.00
Q2.24
+220%
359
vs -298.00
Q3.24
+152%
123
vs -235.00
Q4.24
+2712%
2.4K
vs 86.32
Q1.25
+82%
298
vs 164
Q2.25
-12%
314.45
vs 359
Q3.25
+142%
297.29
vs 123
Sales Growth
YoY
Current
Estimates
Q2.23
+44%
77B vs 53.4B
Q3.23
+2%
90.3B vs 88.8B
Q4.23
+102%
126.8B vs 62.8B
Q1.24
+88%
114B vs 60.8B
Q2.24
+74%
134B vs 77B
Q3.24
+51%
136.6B vs 90.3B
Q4.24
+29%
163B vs 126.8B
Q1.25
+27%
144.4B vs 114B
Q2.25
+24%
166.5B vs 134B
Q3.25
+32%
180.8B vs 136.6B
Return on Equity
QoQ
Q2.23
-8%
-0.08
vs -0.01
Q3.23
-5%
-0.05
vs -0.08
Q4.23
+2%
0.02
vs -0.05
Q1.24
+4%
0.04
vs 0.02
Q2.24
+8%
0.08
vs 0.04
Q3.24
+3%
0.03
vs 0.08
Q4.24
+35%
0.35
vs 0.03
Q1.25
+4%
0.04
vs 0.35
Institutionnal Ownership
Forecast
519%2026-Revenue
987%2026-EPS
-252%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Quote Panel
Key Metrics
Relative Strength
326030.KS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy. The company was founded in 2011 and is headquartered in Seongnam, South Korea. SK Biopharmaceuticals Co., Ltd. operates as subsidiary of SK Inc.
KSC
3300.00Â ( 3.45%)
Pre-market NaN$0.00 (0.00%)
Relative Strenght
Volume Buzz
54%
Earning Acce
No
Dist 52w H.
24%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How 326030.KS compares to sector?